Novo Nordisk

A Quality Compounder Marked Down on Overblown Fears

bactrian

Invested

Community Contributor

Published

01 Aug 25

Updated

05 Aug 25

bactrian's Fair Value

US$120.72

58.7% undervalued

05 Aug

US$49.87

-61.6%

2.2%

Author's Valuation

US$120.7

58.7% undervalued

bactrian's Fair Value

Narrative

Updates0

bactrian'sFair Value

US$120.7

58.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.88%

Pharma revenue growth rate

1.00%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.45%

Calculation

DKK 417.35b

Earnings '35

15.00x

PE Ratio '35

DKK 6.26t

Market Cap '35

DKK 6.26t

Market Cap '35

4.26b

No. shares '35

DKK 1.47k

Share Price '35

DKK 1.47k Share Price '35

Discounted to 2025 @ 6.40% p.a.

DKK 789.68

Fair Value '25

DKK 789.68 Fair Value '25

Converted to USD @ 0.1529 DKK/USD Exchange Rate

US$120.74

Fair Value '25